Stephane Bancel Sells 40,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $192.06, for a total transaction of $7,682,400.00. Following the completion of the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $1,039,418,348.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Stephane Bancel also recently made the following trade(s):

  • On Wednesday, January 11th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $185.02, for a total transaction of $7,400,800.00.
  • On Wednesday, January 4th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $178.11, for a total transaction of $7,124,400.00.
  • On Thursday, December 29th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $179.85, for a total transaction of $7,194,000.00.
  • On Thursday, December 22nd, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $205.31, for a total transaction of $8,212,400.00.
  • On Friday, November 25th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $176.04, for a total transaction of $7,041,600.00.
  • On Wednesday, November 23rd, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $176.20, for a total transaction of $7,048,000.00.
  • On Thursday, November 3rd, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $147.10, for a total transaction of $5,884,000.00.
  • On Wednesday, October 26th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $142.51, for a total transaction of $5,700,400.00.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $193.98 on Friday. The firm’s 50-day moving average price is $185.39 and its 200-day moving average price is $160.95. Moderna, Inc. has a 1-year low of $115.03 and a 1-year high of $217.25. The firm has a market capitalization of $74.52 billion, a P/E ratio of 7.02 and a beta of 1.71. The company has a current ratio of 2.10, a quick ratio of 1.80 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNAGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $2.53 earnings per share for the quarter, missing the consensus estimate of $3.04 by ($0.51). The company had revenue of $3.36 billion for the quarter, compared to analyst estimates of $3.33 billion. Moderna had a net margin of 55.00% and a return on equity of 70.03%. Equities research analysts anticipate that Moderna, Inc. will post 21.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the business. Total Clarity Wealth Management Inc. bought a new stake in shares of Moderna during the second quarter worth about $25,000. Ronald Blue Trust Inc. increased its position in shares of Moderna by 307.4% during the fourth quarter. Ronald Blue Trust Inc. now owns 220 shares of the company’s stock worth $26,000 after acquiring an additional 166 shares in the last quarter. Evoke Wealth LLC grew its position in Moderna by 100.8% in the 3rd quarter. Evoke Wealth LLC now owns 239 shares of the company’s stock worth $28,000 after purchasing an additional 120 shares in the last quarter. Guardian Wealth Advisors LLC bought a new stake in Moderna in the 3rd quarter worth about $28,000. Finally, FinTrust Capital Advisors LLC grew its position in Moderna by 754.5% in the 2nd quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock worth $31,000 after purchasing an additional 166 shares in the last quarter. 63.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MRNA has been the topic of a number of research reports. Piper Sandler boosted their target price on shares of Moderna from $214.00 to $217.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 20th. Chardan Capital boosted their target price on shares of Moderna from $191.00 to $208.00 and gave the stock a “neutral” rating in a research note on Wednesday. Cowen decreased their target price on shares of Moderna from $165.00 to $145.00 in a research note on Thursday, October 20th. SVB Leerink lifted their price target on shares of Moderna from $102.00 to $111.00 and gave the stock a “market perform” rating in a report on Wednesday. Finally, Bank of America lifted their price target on shares of Moderna from $160.00 to $182.00 in a report on Tuesday, November 15th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $191.92.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Read More

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.